In similar studies, USP53 was also shown to have proliferative inhibitory effects on lung cancer, renal clear cell carcinoma, hepatocellular carcinoma and esophageal carcinoma [14–17]. This evidence concerns the gene USP53 and hepatocellular carcinoma.